Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia
Sponsor: Seattle Children's Hospital
Summary
Patients with relapsed or refractory CD 19+ leukemia who have achieved remission after CD19 CAR-T cell treatment sometimes relapse because the CD 19 CAR-T cells decrease in number over time. Study PLAT-03 will test whether administering T cell antigen presenting cells (T-APCs) at intervals following treatment with CAR-T cells improves CD 19 CAR-T cell persistence and reduces the incidence of leukemia relapse.
Official title: Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-03: A Pilot Feasibility and Safety Study of CD19t T-Antigen Presenting Cells (T-APCs) Following CAR T Cell Immunotherapy for CD19+ Leukemia
Key Details
Gender
All
Age Range
1 Year - 30 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2017-08-04
Completion Date
2033-07
Last Updated
2025-06-17
Healthy Volunteers
No
Conditions
Interventions
T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)
Autologous CD4 and CD8 T cells transduced to express a truncated CD19 (CD19t) Transgene
Locations (1)
Seattle Children's Hospital
Seattle, Washington, United States